BlissCo is currently trading on the Canadian Stock Exchange as BlissCo Cannabis Corp. (BLIS).

BlissCo Cannabis Corp Receives its Cultivars at its Langley Facility

Vancouver, British Columbia – May 7, 2018– BlissCo Cannabis Corp. (CSE: BLIS) is pleased to announce that the company’s wholly-owned subsidiary, Bliss Co Holdings Ltd. (“BlissCo”), has received its order of cuttings at its facility in Langley. BlissCo received the cuttings on May 2, 2018, from 7ACRES which is a Licensed Producer and wholly owned subsidiary of The Supreme Cannabis Company, Inc. (TSX.V: FIRE).

These cuttings have been proven through the 7ACRES team and bred by world-renowned seed breeders Dinafem and Paradise Seeds  .

“The cuttings from 7ACRES are doing well in their new environment. We are thrilled that the plants arrived so quickly, just 34 days after BlissCo was licensed on March 29, 2018. This will enable the team to start the process to earn our sales license in an expedient manner.” said Damian Kettlewell, BlissCo CEO.

Statistics Canada estimates that Canadians spent about $5.7 billion on cannabis in 2017, despite the substance’s pending legal status.

“BlissCo has strategically acquired a range of proven CBD strains that vary from high to low CBD levels, including a 1:1 THC:CBD profile to add to our genetic library. The cannabis cultivars received by BlissCo stay true to BlissCo’s brand promise of high quality, clean and nutrient-rich dried medicinal cannabis crafted for the experience that our patients are looking for. ” added Kettlewell.

The Hemp Business Journal estimated that the global market for CBD will grow to $2.1 billion by 2020.

These cuttings will complement the four premium strains with high THC profiles which the company intends to purchase from its strategic partner The Supreme Cannabis Company, Inc . as part of a two-year, 3,000 kilogram supply agreement.

“We are seeing incredible momentum within the BlissCo team and are beginning to attract an increasing number of world-class partners and advisors who will play a key role in helping us to serve our unique customer segment. The arrival of these cultivars is just one more critical step on the way to realizing our grand vision.” added Kettlewell.

About BlissCo

BlissCo (CSE: BLIS) earned its Access to Cannabis for Medical Purposes Regulation ACMPR License to Cultivate on Thursday, March 29, 2018. BlissCo’s ACMPR facility in Langley, B.C. is designed to be a high-volume packager, processor and distributor of medical cannabis and


adult use cannabis when it is legal in Canada, which is currently anticipated to be by August 2018 at the earliest. BlissCo has a two - year supply agreement with The Supreme Cannabis Company Inc. (TSX.V: FIRE) to purchase 3,000 kilograms of premium dried cannabis.

BlissCo will apply to expand its license to cannabis oil production in Q2 2018 and will apply for its cannabis sales license at the earliest appropriate time. BlissCo will focus on high volume sales opportunities in the regulated medical use and adult use cannabis market in Canada when it is legal and is pursuing expansion opportunities in international markets.

On Behalf of the Board of Director


Damian Kettlewell, CEO, Founder & Chair


For further information please contact:

Ariel Jack Lewinski, Business Development & Investor Relations 



Cautionary Statement

This news release contains certain forward-looking information and forward-looking statements within the meaning of applicable securities legislation (collectively “forward-looking statements”). The use of any of the word “will” and similar expressions are intended to identify forward-looking statements. These statements involve known and unknown risks, uncertainties and other factors that may cause actual results or events to differ materially from those anticipated in such forward-looking statements. Such forward-looking statements should not be unduly relied upon. This news release contains forward-looking statements and assumptions pertaining to the following: the ability to execute on our strategic plans and the impact on our future operations, capital expenditures, receipt of a cannabis oil license and a license to sell dried cannabis and other objectives. Actual results achieved may vary from the information provided herein as a result of numerous known and unknown risks and uncertainties and other factors. The Company believes the expectations reflected in those forward-looking statements are reasonable, but no assurance can be given that these expectations will prove to be correct. The Company does not undertake to update these forward-looking statements, except as required by law.

The CSE has in no way passed upon the merits of the proposed transaction and has neither approved nor disapproved the contents of this press release.

See All Investor Updates


As Canada is primed as a global leader and first mover in the cannabis industry, BlissCo is uniquely poised in the rapidly growing multi-billion dollar market and in various international markets as cannabis regulations progress.

BlissCo, founded in 2013, is a Canadian vertically integrated cultivation, extraction and distribution focused cannabis brand that earned its Access to Cannabis for Medical Purposes Regulations (ACMPR) license to cultivate from Health Canada on March 29, 2018.

BlissCo's state-of-the-art production facility, located in Metro Vancouver, is purposefully designed as a hub for research, cultivation, processing, extraction, packaging and distribution.

Now with the ACMPR license to cultivate, BlissCo will commence its operation to harvest premium cannabis within its' urban facility in Metro Vancouver.  BlissCo also has a multi-year supply agreement in place with a Canadian Licensed Producer of characteristically sun-grown premium medicinal cannabis to purchase supply in large volumes (news release). This premium bulk cannabis will be brought to our secure and pristine facility in British Columbia for processing and then be packaged for sale and distribution to our growing patient list when BlissCo has appropriately received its license for sale. 

BlissCo was founded with the assistance of a team of advisors, including medical and naturopathic doctors, has intentionally engaged with the medical community to understand how to contribute to improved patient health with medicinal cannabis products. A large part of our strategy for growth centres on how to securely integrate and collaborate with the healthcare system.

The BlissCo team has deep domain expertise in the critical category success areas:

  • Multi-province controlled substance distribution (BC and Alberta)
  • Cultivation and product safety, consistency and security
  • Indoor cultivation, controlled environments ensuring high standards &  consistent products.
  • Quality assurance, product safety, 3rd Party GMP Audits & Certifications.




Strategic partnership with the Supreme Cannabis Company

Trading on Canadian Securities Exchange (CSE:BLIS)

ACMPR License to Produce earned


Cannabis plant starting material to arrive at BlissCo's facility and growing commences. 

ACMPR Cannabis Oil Extraction License application submitted


Sign agreement to export 720 kilograms of medical cannabis to Germany


ACMPR License to Sell application submitted

Sign supply agreement with GreenSeal Cannabis

Sign e-commerce and technology service agreement with Namaste Technologies (TSXV: N)


Confirmation of Readiness for Inspection received from Health Canada

Confirmation of Readiness for License from Health Canada

Close on purchasing facility for $2.4m

Earn Building Permit from Township of Langley
Commence Construction


ACMPR Licensed Submitted